Keywords: USA, Johnson & Johnson, Ortho-McNeil, Topamax, Solvay, Schwartz, Off-label promotion, Unapproved drug reimbursement
Johnson & Johnson subsids to pay $81.5 million over off-label promo of Topamax, and Solvay unit agrees $22 million settlement on Deponit and Hyoscyamine
Article | 30 April 2010
US drugmakers Ortho-McNeil Pharmaceutical and its parent Ortho-McNeil-Janssen Pharmaceuticals, both subsidiaries of Johnson & Johnson, have agreed to pay a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
